---
layout: default
title: Inclisiran
parent: 僅模型預測 (L5)
nav_order: 324
evidence_level: L5
indication_count: 10
---

# Inclisiran
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the report as a direct content-generation task following the prescribed template (no additional skill applies — this is authoring output per explicit formatting instructions already provided in the prompt).

I reviewed the evidence pack in full, including all 10 ranked predictions and the `repurposing_rationale` text embedded in the JSON itself. One thing worth flagging before the report: **rank 1** (`potassium deficiency disease`) is the mechanically "top" prediction per the score, but the evidence pack's own rationale explicitly calls it likely model noise (zero trials, zero literature, no plausible PCSK9 mechanism). I followed the template's rule to use `predicted_indications[0]` for the headline fields, but wrote the "Why is this reasonable" and "Conclusion" sections honestly — reflecting the *actual* evidence level (L5, Hold) rather than overstating confidence. I also surfaced rank 8 (`aortic malformation`, L2, 2 registered Phase 3 trials) as a separate, better-evidenced signal worth noting in the next-steps section, since burying it would omit the most decision-relevant fact in the pack.

---

# Inclisiran: From Hypercholesterolemia to Potassium Deficiency Disease

## One-Sentence Summary

> Inclisiran is a liver-targeted small interfering RNA (siRNA) that lowers LDL cholesterol by silencing PCSK9 synthesis, with established use in hypercholesterolemia and familial hypercholesterolemia.
> The TxGNN model's top-ranked prediction for this candidate is **Potassium Deficiency Disease**,
> but **0 clinical trials** and **0 publications** currently support this specific drug–disease link, and the evidence pack itself flags the prediction as likely model noise.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not registered in Saudi Arabia (unmarketed); established use per linked trial data: Hypercholesterolemia / elevated LDL-C (PCSK9-targeting siRNA) |
| Predicted New Indication | Potassium Deficiency Disease |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for inclisiran is not available in this evidence pack (flagged as a High-severity data gap). Based on information embedded elsewhere in the pack (trial titles referencing "elevated LDL-Cholesterol" and "familial hypercholesterolemia"), inclisiran is understood to act as a hepatocyte-targeted siRNA that silences PCSK9 mRNA translation, increasing LDL-receptor recycling and lowering circulating LDL cholesterol.

For this specific prediction, the mechanistic case is weak. There is no known biological pathway connecting hepatic PCSK9 silencing to potassium or electrolyte homeostasis, and the rationale text in the evidence pack itself concludes this ranking is most likely a **false positive arising from knowledge-graph embedding proximity** rather than a genuine pharmacological signal — no clinical trial or literature evidence of any kind was found for this pairing.

This pattern is not unique to rank 1: of the 10 TxGNN-ranked candidates for inclisiran, seven (potassium deficiency disease, esophageal disease, atypical coarctation of aorta, migraine disorder, non-syndromic esophageal malformation, migraine with brainstem aura, esophageal ulcer, Raynaud disease) return **zero** supporting trials or literature and are explicitly annotated as noise or unsupported theoretical extensions. One candidate (migraine with/without aura susceptibility, rank 7) surfaced 20 PubMed hits, but on review all concern shared genetics between epilepsy and migraine — none mention PCSK9 or inclisiran. The only candidate with real supporting trial data is rank 8, **aortic malformation** (L2, 2 registered Phase 3 pediatric studies) — though even there, the trials are for homozygous/heterozygous familial hypercholesterolemia, with aortic pathology arising as a secondary consequence of untreated LDL-C rather than a direct drug target. Taken together, the evidence for this drug's repurposing candidates at the current data cutoff is sparse, and the top-ranked prediction specifically should not be interpreted as clinically actionable.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Inclisiran is not currently marketed in Saudi Arabia — no SFDA authorization records are available in this evidence pack.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked TxGNN prediction (potassium deficiency disease) has no clinical trial or literature support, and the mechanistic rationale in the evidence pack itself assesses it as likely model noise rather than a genuine signal. No other candidate in the top 10 currently reaches an evidence level beyond L2, and that one candidate (aortic malformation, rank 8) reflects a secondary/indirect disease association rather than a direct novel indication.

**To proceed, the following is needed:**
- SFDA-equivalent package insert warnings, precautions, and contraindications for inclisiran (currently a Blocking data gap — required before any S1 safety screening)
- Confirmed mechanism-of-action documentation from DrugBank or manufacturer labeling (currently a High-severity data gap)
- If pursuing rank 8 (aortic malformation) as a research question: clarification of whether the signal is driven by direct PCSK9 mechanism or is purely secondary to LDL-C-driven aortic valve pathology in familial hypercholesterolemia, plus outcome data from NCT06597019 and NCT06597006 once available
- Re-screening of lower-ranked candidates against updated TxGNN model runs, given the high proportion of zero-evidence predictions in this candidate set
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

